Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 193-197

  Naito, Shokichi ^a   Kamata, Mariko ^a   Furuya, Masako ^a   Hayashi, Miyuki ^a   Kuroda, Masayuki ^b,c   Bujo, Hideaki ^b   Kamata, Kouju ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Circulating lipoprotein profile; Cys74Tyr; Familial LCAT deficiency; Fat restriction diet; Novel gene mutation; Renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGAR GEL ELECTROPHORESIS; ANEMIA; ARTICLE; CASE REPORT; CHOLESTEROL ESTERIFICATION; CORNEA OPACITY; DYSPNEA; ENZYME ACTIVITY; ENZYME SUBSTRATE; FAMILY HISTORY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MENTAL DEFICIENCY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEINURIA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHOLESTEROL; CORNEAL OPACITY; DIET, FAT-RESTRICTED; DISULFIDES; ESTERIFICATION; FEMALE; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; LIPOPROTEINS; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; POINT MUTATION; PROTEINURIA;

EID: 84876807971     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.034     Document Type: Article

References (29)

1. Glomset J. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophys Acta 1962, 65:128-135.
2. Santamarina-Fojo S., Hoeg J.M., Assman G., Brewer H.B. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In the metabolic and molecular bases of inherited disease 2001, 2817-2833. McGraw-Hill Inc., New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
3. Norum K.R., Gjone E. The effect of plasma transfusion on the plasma cholesterol esters in patients with familial plasma lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest 1968, 22:339-342.
4. Murayama N., Asano Y., Kato K., et al. Effects of plasma infusion on plasma lipids, apoproteins and plasma enzyme activities in familial lecithin:cholesterol acyltransferase deficiency. Eur J Clin Invest 1984, 14:122-129.
5. Kuroda M., Aoyagi Y., Asada S., et al. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Open Gene Ther 2011, 4:1-10.
6. Kuroda M., Bujo H., Aso M., Saito Y. Adipocytes as a vehicle for exvivo gene therapy: novel replacement therapy for diabetes and other metabolic diseases. JDiabetes Invest 2011, 2:333-340.
7. Yee M.S., Pavitt D.V., Richmond W., et al. Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy. Atherosclerosis 2009, 205:528-532.
8. Aranda P., Valdivielso P., Pisciotta L., et al. Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol 2008, 69:213-218.
9. Miarka P., Idzior-Waluś B., Kuźniewski M., Waluś-Miarka M., Klupa T., Sułowicz W. Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Exp Nephrol 2011, 15:424-429.
10. Holleboom A.G., Kuivenhoven J.A., van Olden C.C., et al. Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase. Atherosclerosis 2011, 216:161-165.
11. Nagasaki T., Akanuma Y. Anew colorimetric method for determination of plasma lecithin-cholesterol acyltransferase activity. Clinica Chim Acta 1977, 75:371-375.
12. Narayan K.A., Narayan S., Kummerou F.A. Disk electrophoresis of human serum lipoproteins. Nature 1965, 205:246-248.
13. Asada S., Kuroda M., Aoyagi Y., et al. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes invitro. Mol Genet Metab 2011, 102:229-231.
14. Winkler K., Nauck M., Siekmeier R., März W., Wieland H. Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis. JLipid Res 1995, 36:1839-1847.
15. Contois J.H., Gillmor R.G., Moore R.E., Contois L.R., Macer J.L., Wu A.H. Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis. Clin Chim Acta 1999, 282:1-14.
16. Kido T., Kurata H., Matsumoto A., et al. Lipoprotein analysis using agarose gel electrophoresis and differential staining of lipids. JAtheroscler Thromb 2001, 8:7-13.
17. Zhang B., Matsunaga A., Saku K., Nakano S., Yamada T. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler Thromb Vasc Biol 2004, 24:e144-146.
18. Chevet D., Ramee M.P., Le Pogamp P., et al. Hereditary lecithin:cholesterol acyltransferase deficiency. Report of a new family with two afflicted sisters. Nephron 1978, 212:212-219.
19. Gjone E. Familial LCAT deficiency. Acta Med Scand 1973, 194:353-356.
20. Hovig T., Gjone E. Familial plasma lecithin: cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen. Acta Pathol Microbiol Scand A 1973, 81:681-697.
21. Magil A., Chase W., Frohlich J. Unusual renal biopsy findings in a patient with familial lecithin:cholesterol acyltransferase deficiency. Hum Pathol 1982, 13:283-285.
22. Hovig T., Blomhoff J.P., Holme R., et al. Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidneys of patients with hepatorenal syndrome. Lab Invest 1978, 38:540-549.
23. Yang C.Y., Manoogian D., Pao Q., et al. Lecithin:cholesterol acyltransferase. Functional regions and a structural model of the enzyme. JBiol Chem 1987, 262:3086-3091.
24. Holleboom A.G., Kuivenhoven J.A., Peelman F., et al. High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in the Netherlands: identification and characterization of eight novel mutations. Hum Mutat 2011, 32:1290-1298.
25. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000, 1529:245-256.
26. Jin L., Shieh J.J., Grabbe E., Adimoolam S., Durbin D., Jonas A. Surface plasmon resonance biosensor studies of human wild-type and mutant lecithin cholesterol acyltransferase interactions with lipoproteins. Biochemistry 1999, 38:15659-15665.
27. Peelman F., Vanloo B., Perez-Mendez O., et al. Characterization of functional residues in the interfacial recognition domain of lecithin cholesterol acyltransferase (LCAT). Protein Eng 1999, 12:71-78.
28. Adimoolam S., Jonas A. Identification of a domain of lecithin-cholesterol acyltransferase that is involved in interfacial recognition. Biochem Biophys Res Commun 1997, 232:783-787.
29. Gröne E.F., Walli A.K., Gröne H.J., Miller B., Seidel D. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994, 107:1-13.